Breast Cancer Symposium - Enhancing Clinical Care Through Collaboration

The Pros and Cons of pCR

Drs. Norman Wolmark and Clifford Hudis debate to what extent pathologic complete response (pCR) to neoadjuvant therapy can be considered a surrogate for improvements in disease-free and overall survival. Dr. Wolmark believes this use of pCR is transformative to trial design and to implications for care. Dr. Hudis, however, believes that there are “serious risks to the societal well-being with this approach.”